Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Priothera Receives Fast Track Designation for Mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, […]
FDA Approves Roche’s Evrysdi for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
New Clinical Trials Deal Struck to Better Protect World From Future Pandemics
Millions of people across the world will be better protected from future pandemics thanks to […]
Novartis UK Launches New Heart Failure Insights Tool to Address Health Inequalities in England
Novartis UK has today announced the launch of a new heart failure Health Inequalities Insights […]
NRG Therapeutics Announces £2.68m Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased […]
MediCardia Health Inc. Integrates Optimize EP C-aRM to Develop First of it's Kind, Comprehensive Connected Cardiac Care Platform
MediCardia Health Inc., a pioneer in global digital health, announced today that the Company has […]
Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling […]
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers
Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or […]
New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-class Bispecific Antibody for People With Aggressive Lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on its investigational […]
Roche’s Polivy Combination Approved by European Commission for People With Previously Untreated Diffuse Large B-cell Lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more